Suppr超能文献

蛋白C抑制剂通过抑制人血浆中血栓调节蛋白诱导的蛋白C活化而发挥促凝作用。

Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma.

作者信息

Elisen M G, von dem Borne P A, Bouma B N, Meijers J C

机构信息

Department of Haematology, University Hospital and Institute of Biomembranes, Utrecht University, Utrecht, The Netherlands.

出版信息

Blood. 1998 Mar 1;91(5):1542-7.

PMID:9473218
Abstract

Protein C inhibitor (PCI), which was originally identified as an inhibitor of activated protein C, also efficiently inhibits coagulation factors such as factor Xa and thrombin. Recently it was found, using purified proteins, that the anticoagulant thrombin-thrombomodulin complex was also inhibited by PCI. The paradoxical inhibitory effect of PCI on both coagulant and anticoagulant proteases raised questions about the role of PCI in plasma. We studied the role of thrombomodulin (TM)-dependent inhibition of thrombin by PCI in a plasma system. Clotting was induced by addition of tissue factor to recalcified plasma in the absence or presence of TM, and clot formation was monitored using turbidimetry. In the absence of TM, PCI-deficient plasma showed a slightly shorter coagulation time compared with normal plasma. Reconstitution with a physiologic amount of PCI gave normal clotting times. Addition of PCI to normal plasma and protein C-deficient plasma resulted in a minor prolongation of the clotting time. This suggested that PCI can act as a weak coagulation inhibitor in the absence of TM. TM caused a strong anticoagulant effect in normal plasma due to thrombin scavenging and activation of the protein C anticoagulant pathway. This effect was less pronounced when protein C-deficient plasma was used, but could be restored by reconstitution with protein C. When PCI was added to protein C-deficient plasma in the presence of TM, a strong anticoagulant effect of PCI was observed. This anticoagulant effect was most likely caused by the TM-dependent thrombin inhibition by PCI. However, when PCI was added to normal plasma containing TM, a strong procoagulant effect of PCI was observed, due to the inhibition of protein C activation. PCI-deficient plasma was less coagulant in the presence of TM. A concentration-dependent increase in clotting time was observed when PCI-deficient plasma was reconstituted with PCI. The combination of these results suggest that the major function of PCI in plasma during coagulation is the inhibition of thrombin. A decreased generation of activated protein C is a procoagulant consequence of the TM-dependent thrombin inhibition by PCI. We conclude that TM alters PCI from an anticoagulant into a procoagulant during tissue factor-induced coagulation.

摘要

蛋白C抑制剂(PCI)最初被鉴定为活化蛋白C的抑制剂,它也能有效抑制凝血因子,如因子Xa和凝血酶。最近,通过使用纯化蛋白发现,抗凝性凝血酶-血栓调节蛋白复合物也受到PCI的抑制。PCI对凝血和抗凝蛋白酶的这种矛盾抑制作用引发了关于PCI在血浆中作用的疑问。我们在血浆系统中研究了PCI对血栓调节蛋白(TM)依赖性凝血酶抑制作用的作用。在不存在或存在TM的情况下,向重新钙化的血浆中添加组织因子诱导凝血,并使用比浊法监测凝块形成。在不存在TM的情况下,与正常血浆相比,PCI缺陷血浆的凝血时间略短。用生理量的PCI重构可使凝血时间正常。向正常血浆和蛋白C缺陷血浆中添加PCI会导致凝血时间轻微延长。这表明在不存在TM的情况下,PCI可作为一种弱凝血抑制剂。由于凝血酶清除和蛋白C抗凝途径的激活,TM在正常血浆中产生强大的抗凝作用。当使用蛋白C缺陷血浆时,这种作用不太明显,但可通过用蛋白C重构来恢复。当在存在TM的情况下向蛋白C缺陷血浆中添加PCI时,观察到PCI具有强大的抗凝作用。这种抗凝作用很可能是由PCI对TM依赖性凝血酶的抑制引起的。然而,当将PCI添加到含有TM的正常血浆中时,由于蛋白C激活的抑制,观察到PCI具有强大的促凝作用。在存在TM的情况下,PCI缺陷血浆的凝血性较低。当用PCI重构PCI缺陷血浆时,观察到凝血时间呈浓度依赖性增加。这些结果的综合表明,PCI在凝血过程中在血浆中的主要功能是抑制凝血酶。PCI对TM依赖性凝血酶的抑制导致活化蛋白C生成减少是一种促凝后果。我们得出结论,在组织因子诱导的凝血过程中,TM将PCI从抗凝剂转变为促凝剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验